WAT

Waters Corporation [WAT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

WAT Stock Summary

Top WAT Correlated Resources

WAT


Top 10 Correlated ETFs

WAT


Top 10 Correlated Stocks

WAT


In the News

01:06 29 Nov 2023 WAT

Waters Corporation to Present at the Evercore ISI HealthCONx 2023 Health Care Conference

MILFORD, Mass. , Nov. 16, 2023 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra Ph.D.

02:17 29 Nov 2023 WAT

Waters (WAT) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

Waters' (WAT) Q3 results benefit from a strong Pharmaceutical market, as well as a strong contribution from the Wyatt acquisition.

12:59 29 Nov 2023 WAT

Waters Corporation (WAT) Q3 2023 Earnings Call Transcript

Waters Corporation (NYSE:WAT ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Caspar Tudor – Head-Investor Relations Udit Batra – President and Chief Executive Officer Amol Chaubal – Senior Vice President and Chief Financial Officer Conference Call Participants Vijay Kumar – Evercore ISI Dan Brennan – TD Cowen Matt Sykes – Goldman Sachs Derik De Bruin – Bank of America Rachel Vatnsdal – JPMorgan Eve Burstein – Bernstein Research Operator Good morning. Welcome to the Waters Corporation Third Quarter 2023 Financial Results Conference Call.

11:17 29 Nov 2023 WAT

Curious about Waters (WAT) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Evaluate the expected performance of Waters (WAT) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

03:02 29 Nov 2023 WAT

Waters (WAT) to Report Q3 Earnings: What's in the Offing?

Waters' (WAT) third-quarter 2023 results are likely to reflect strength in liquid chromatography instruments and mass spectrometers amid uncertainties in the global economy.

12:11 29 Nov 2023 WAT

Among the S&P 500, these 20 companies have made the best use of investors' money

There is no easy way to select individual stocks. Measures of financial quality can highlight companies that are worth a closer look, but a decision to commit money must also take into consideration both recent developments and a look ahead.

12:47 29 Nov 2023 WAT

Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move

Waters (WAT) partners with the University of San Agustin to provide the latter with technology equipment in its newly developed mass spectrometry imaging center in the Philippines.

06:07 29 Nov 2023 WAT

Waters Corporation: Buybacks Ceased, Incremental Returns Languishing (Rating Downgrade)

Waters Corporation has pushed lower into H2 FY'23, in continuation of the longer-term downtrend. WAT's acquisition of Wyatt Technology was a large premium that to me signaled a lack of profitable investment runway. Despite exceptional returns on existing capital, the incremental returns don't match these numbers, clamping earnings and FCF growth.

06:00 29 Nov 2023 WAT

Waters Has Made Progress In Repositioning The Business, And The Valuation Is Much More Accommodating Now

Waters Corporation has seen a significant hit to its share price as momentum has left the life sciences tools space and as spending from the key biopharma end-market has corrected. Biopharma spending likely won't return to the torrid pace of the boom years, but ongoing investments into discovery tools, production equipment, and QA/QC equipment should drive healthy growth. The company's presence in industrial markets, such as food and water quality testing, provides a steady source of profitability and growth potential in areas like battery testing and sustainable polymers.

09:02 29 Nov 2023 WAT

Waters Corporation (WAT) Bank of America Global Healthcare Conference 2023 (Transcript)

Waters Corporation (NYSE:WAT ) Bank of America Global Healthcare Conference 2023 Call September 13, 2023 8:20 AM ET Company Participants Udit Batra - President and Chief Executive Officer Conference Call Participants Derik De Bruin - Bank of America Merrill Lynch Derik De Bruin Good afternoon, and welcome to Bank of America's Global Healthcare Conference Community Live from London. I'm Derik De Bruin, the Senior U.S. Life Sciences and Diagnostics Tools analyst, and it is my pleasure to welcome our next company, which is Waters Corp. Today with me, we have Dr. Udit Batra, President and CEO of Waters.

WAT Financial details

Company Rating
Strong Buy
Market Cap
16.58B
Income
653.09M
Revenue
3B
Book val./share
15.32
Cash/share
5.71
Dividend
-
Dividend %
-
Employees
8.2K
Optionable
No
Shortable
Yes
Earnings
13 Feb 2024
P/E
24.97
Forward P/E
21.34
PEG
-147.85
P/S
5.45
P/B
18.01
P/C
48.33
P/FCF
41.82
Quick Ratio
0.39
Current Ratio
0.6
Debt / Equity
5.54
LT Debt / Equity
2.78
-
-
EPS (TTM)
11.06
EPS next Y
12.93
EPS next Q
4.25
EPS this Y
4.89%
EPS next Y
16.91%
EPS next 5Y
29.85%
EPS last 5Y
8.88%
Revenue last 5Y
4.2%
Revenue Q/Q
-3.9%
EPS Q/Q
-10.94%
-
-
-
-
SMA20
10.05%
SMA50
0.78%
SMA100
3.02%
Inst Own
64.71%
Inst Trans
0.69%
ROA
15%
ROE
94%
ROC
0.42%
Gross Margin
59%
Oper. Margin
28%
Profit Margin
22%
Payout
-
Shs Outstand
59.13M
Shs Float
58.87M
-
-
-
-
Target Price
340
52W Range
231.9-353.71
52W High
-21.83%
52W Low
+19.46%
RSI
60.92
Rel Volume
0.61
Avg Volume
525.99K
Volume
319.72K
Perf Week
3.66%
Perf Month
8.14%
Perf Quarter
7.32%
Perf Half Y
7.97%
-
-
-
-
Beta
0.898
-
-
Volatility
7.17%, 11.77%
Prev Close
-0.38%
Price
275.95
Change
-0.95%

WAT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
31.4335.5938.0945.2449.54
Net income per share
7.718.768.411.2511.8
Operating cash flow per share
7.859.5112.7312.1410.2
Free cash flow per share
6.197.099.959.47.14
Cash per share
22.544.997.149.258.03
Book value per share
20.36-3.23.745.978.41
Tangible book value per share
12.53-12.02-7.58-5.08-2.55
Share holders equity per share
20.36-3.23.745.978.41
Interest debt per share
29.9649.6225.2425.5728.16
Market cap
14.52B15.8B15.36B22.94B20.55B
Enterprise value
16.02B17.15B16.28B23.96B21.72B
P/E ratio
24.4626.6829.4633.1129.03
Price to sales ratio
66.576.58.246.91
POCF ratio
24.0324.5719.4330.733.6
PFCF ratio
30.4632.9724.8539.6247.99
P/B Ratio
9.27-73.0666.1862.4240.73
PTB ratio
9.27-73.0666.1862.4240.73
EV to sales
6.627.126.888.67.31
Enterprise value over EBITDA
20.0321.1620.6924.5521.38
EV to operating cash flow
26.5126.6620.632.0635.51
EV to free cash flow
33.635.7826.3441.3750.72
Earnings yield
0.040.040.030.030.03
Free cash flow yield
0.030.030.040.030.02
Debt to equity
1.47-15.396.614.193.27
Debt to assets
0.621.30.540.50.5
Net debt to EBITDA
1.881.661.171.041.15
Current ratio
2.260.741.642.262.11
Interest coverage
75.2326.619.6825.1223.12
Income quality
1.021.091.521.080.86
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.060.060.060.060.06
Intangibles to total assets
0.160.230.250.220.2
Capex to operating cash flow
-0.21-0.25-0.22-0.23-0.3
Capex to revenue
-0.05-0.07-0.07-0.06-0.06
Capex to depreciation
-1.18-1.56-1.27-1.28-1.41
Stock based compensation to revenue
0.020.020.020.010.01
Graham number
59.4325.126.5838.8747.25
ROIC
0.170.190.30.350.33
Return on tangible assets
0.190.30.240.290.27
Graham Net
1.91-27.14-25.49-24.69-25.43
Working capital
1.45B-435.73M515.76M857.52M874.26M
Tangible asset value
964.74M-812.61M-470.86M-312.71M-153.24M
Net current asset value
434.94M-1.53B-1.29B-1.19B-1.12B
Invested capital
1.47-15.396.614.193.27
Average receivables
551.07M578.03M580.53M592.98M667.77M
Average payables
66.35M58.58M60.61M84.51M95.05M
Average inventory
280.93M306.06M312.42M330.19M405.9M
Days sales outstanding
85.7289.1488.4780.2788.78
Days payables outstanding
25.0717.726.1830.5527.28
Days of inventory on hand
107.22115.76110.32112.38133.26
Receivables turnover
4.264.094.134.554.11
Payables turnover
14.5620.6313.9411.9513.38
Inventory turnover
3.43.153.313.252.74
ROE
0.38-2.742.251.891.4
Capex per share
-1.66-2.42-2.78-2.73-3.06

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-10-012022-12-312023-04-012023-07-01 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
11.8514.4711.612.5812.04
Net income per share
2.613.832.392.562.28
Operating cash flow per share
2.643.353.330.312.67
Free cash flow per share
1.952.32.75-0.482.03
Cash per share
7.438.118.255.625.71
Book value per share
6.448.510.1613.115.32
Tangible book value per share
-4.15-2.58-1.09-20.25-17.49
Share holders equity per share
6.448.510.1613.115.32
Interest debt per share
27.2328.0150.5446.6685.41
Market cap
16.12B20.32B18.28B15.69B16.2B
Enterprise value
17.29B21.5B19.27B18.08B18.37B
P/E ratio
25.8322.3832.4226.0530.11
Price to sales ratio
22.7523.6726.6921.1822.77
POCF ratio
101.96102.2892.89865.87102.67
PFCF ratio
138.4148.87112.56-550.66135.29
P/B Ratio
41.8440.2930.4720.3417.89
PTB ratio
41.8440.2930.4720.3417.89
EV to sales
24.4125.0428.1424.4125.82
Enterprise value over EBITDA
76.8267.7693.2274.5880.74
EV to operating cash flow
109.39108.1897.94997.96116.42
EV to free cash flow
148.49157.45118.68-634.67153.4
Earnings yield
0.010.010.010.010.01
Free cash flow yield
0.010.010.0100.01
Debt to equity
4.23.274.963.535.54
Debt to assets
0.530.50.90.61.12
Net debt to EBITDA
5.223.694.819.879.53
Current ratio
2.032.111.132.080.6
Interest coverage
20.1627.4916.778.596.76
Income quality
1.010.881.40.121.17
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.060.060.060.060.06
Intangibles to total assets
0.210.20.20.430.43
Capex to operating cash flow
-0.26-0.31-0.17-2.57-0.24
Capex to revenue
-0.06-0.07-0.05-0.06-0.05
Capex to depreciation
-1.29-1.99-1.1-1.2-0.8
Stock based compensation to revenue
0.010.010.020.010.01
Graham number
19.4427.0623.3727.4628.02
ROIC
0.080.110.040.050.03
Return on tangible assets
0.060.090.050.060.05
Graham Net
-26.23-25.71-24.7-45.16-42.45
Working capital
755.7M874.26M189.55M871.8M-992.27M
Tangible asset value
-248.45M-153.24M-64.53M-1.19B-1.03B
Net current asset value
-1.2B-1.12B-1.04B-2.1B-2.08B
Invested capital
4.23.274.963.535.54
Average receivables
620.19M661.91M703.12M688.39M662.36M
Average payables
97.27M94.93M93.43M87.74M80.88M
Average inventory
426.08M448.97M477.57M518.13M540.62M
Days sales outstanding
76.3375.7889.8284.2779.83
Days payables outstanding
28.324.1229.6124.4924.66
Days of inventory on hand
129.6117.79158.06160.47168.14
Receivables turnover
1.181.1911.071.13
Payables turnover
3.183.733.043.683.65
Inventory turnover
0.690.760.570.560.54
ROE
0.40.450.230.20.15
Capex per share
-0.7-1.05-0.58-0.79-0.64

WAT Frequently Asked Questions

What is Waters Corporation stock symbol ?

Waters Corporation is a US stock , located in Milford of Ma and trading under the symbol WAT

Is Waters Corporation buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $340. The lowest prediction is $315 and the highest is $365

What is WAT stock prediction ?

What is Waters Corporation stock quote today ?

Waters Corporation stock price is $275.95 today.

Is Waters Corporation stock public?

Yes, Waters Corporation is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap